Farallon Capital Management’s Dyne Therapeutics DYN Stock Holding History

Farallon Capital Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$181K	Hold	10,000	–	–	﹤0.01%	150
2025 Q4	$196K	Hold	10,000	–	–	﹤0.01%	136
2025 Q3	$127K	Hold	10,000	–	–	﹤0.01%	132
2025 Q2	$95.2K	Hold	10,000	–	–	﹤0.01%	131
2025 Q1	$105K	Sell	10,000 -219,121	-96%	-$3.13M	﹤0.01%	134
2024 Q4	$5.4M	Sell	229,121 -198,879	-46%	-$5.88M	0.02%	87
2024 Q3	$15.4M	Buy	428,000 +422,000	+7,033%	+$16.8M	0.07%	83
2024 Q2	$212K	Buy	+6,000	New	+$174K	﹤0.01%	134
2020 Q4	–	Sell	-200,000	Closed	-$4.04M	–	143
2020 Q3	$4.04M	Buy	+200,000	New	+$4.39M	0.03%	114

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Farallon Capital Management's DYN Position: Q1 2026 in Review

Farallon Capital Management held its Dyne Therapeutics (DYN) position steady in Q1 2026 at 10,000 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #150.

Farallon Capital Management first reported a position in DYN in Q3 2020 and has held it in 9 quarters since. The position peaked at $15.4M in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Farallon Capital Management held 10,000 shares of Dyne Therapeutics worth $181K as of Q1 2026.
Farallon Capital Management left its Dyne Therapeutics share count unchanged in Q1 2026.
Dyne Therapeutics made up ﹤0.01% of Farallon Capital Management's portfolio in Q1 2026, its #150 holding.
Farallon Capital Management first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 9 quarters since.
Farallon Capital Management's Dyne Therapeutics position peaked at $15.4M in Q3 2024.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.